MedTrace Logo

Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects

NCT05576454 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 207

Last updated 2023-08-28

No results posted yet for this study

Summary

To evaluate the pharmacokinetics, safety and immunogenicity of BAT2606 in healthy China male subjects.

Conditions

Interventions

DRUG

Mepolizumab Injection (BAT2606 Injection)

In this group, each subject will receive single subcutaneous injection of 100 mg BAT2606 Injection.

DRUG

Mepolizumab Injection (EU-licensed Nucala)

In this group, each subject will receive single subcutaneous injection of 100 mg Mepolizumab Injection (EU-licensed Nucala®).

DRUG

Mepolizumab Injection (US-licensed Nucala)

In this group, each subject will receive single subcutaneous injection of 100 mg Mepolizumab Injection (US-licensed Nucala®).

Sponsors & Collaborators

Principal Investigators

  • Yanhua Ding, PhD · The First Hospital of Jilin University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-20
Primary Completion
2023-05-26
Completion
2023-06-19

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05576454 on ClinicalTrials.gov